Niagen Bioscience, Inc.
NAGE
$4.78
-$0.04-0.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.38M | 20.43M | 17.73M | 14.11M | 8.55M |
| Total Depreciation and Amortization | 785.00K | 775.00K | 782.00K | 793.00K | 814.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.63M | -280.00K | -1.29M | -1.66M | -389.00K |
| Change in Net Operating Assets | -8.30M | 484.00K | 3.99M | 6.46M | 3.13M |
| Cash from Operations | 13.50M | 21.41M | 21.21M | 19.70M | 12.11M |
| Capital Expenditure | -292.00K | -260.00K | -277.00K | -154.00K | -163.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 20.00K | 20.00K | 20.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -292.00K | -260.00K | -257.00K | -134.00K | -143.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12.00K | -12.00K | -12.00K | -11.00K | -11.00K |
| Issuance of Common Stock | 7.25M | 10.81M | 11.70M | 8.55M | 5.43M |
| Repurchase of Common Stock | -251.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -67.00K | -53.00K | -53.00K | -47.00K | -52.00K |
| Cash from Financing | 6.92M | 10.74M | 11.64M | 8.49M | 5.37M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.13M | 31.89M | 32.59M | 28.05M | 17.34M |